Related Experiment Video

Updated: Sep 20, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

[Clinical implications of trastuzumab]

Toshiaki Saeki1, Shigemitsu Takashima

  • 1Department of Clinical Research & Surgery, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama 790-0007, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2003
PubMed

Insights

Trastuzumab targets C-erbB-2 (HER2/neu) in breast cancer. Combination therapy with paclitaxel improves response rates but increases cardiac risks, necessitating careful patient selection for HER2-positive tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Context:

  • C-erbB-2 (HER2/neu) protein overexpression is a target in solid tumors.
  • HER2/neu is a membrane-bound protein in the EGFR family.
  • Trastuzumab is a monoclonal antibody targeting the extracellular domain of HER2/neu.

Purpose:

  • To investigate the efficacy and safety of Trastuzumab in treating C-erbB-2 positive breast cancer.
  • To evaluate the impact of combination therapy with paclitaxel.
  • To identify patient subgroups likely to respond to Trastuzumab treatment.

Summary:

  • Trastuzumab targets HER2/neu in breast cancer, with response rates around 15% as a single agent.
  • Patients with ICH 2+/FISH positive or ICH 3+ tumors are potential good responders.
  • Combination therapy with paclitaxel significantly increases response rates (>60%) and improves progression-free survival.
  • Trastuzumab can cause severe congestive heart failure, especially when combined with anthracyclines.

Impact:

  • Identifies HER2/neu as a viable therapeutic target in oncology.
  • Demonstrates the benefit of targeted therapy and combination treatments in metastatic breast cancer.
  • Highlights the critical need for cardiac monitoring due to potential Trastuzumab-induced cardiotoxicity.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.